Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI308 vs docetaxel in advanced squamous NSCLC after platinum failure
CTR20170380Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Pulmonary squamous cell carcinoma, sponsored by Innovent Biologics. Started May 2017; status: completed.
02
Drugs
sintilimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20170380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170380.